Moderna shares slump 21% on lowered full-year guidance
Q2 sales and earnings beat estimatesShares plunge on full-year downgradeRSV vaccine doses ship ahead of winterInvestors can be a tough bunch to please, just beating expectations is often not enough.Biotechnology firm Moderna (MRNA)...
02 August 2024